Spero Therapeutics (SPRO) Receivables - Other (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed Receivables - Other for 10 consecutive years, with $1.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other fell 40.99% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2025, down 40.99%, and an annual FY2024 reading of $3.1 million, up 99.68% over the prior year.
- Receivables - Other was $1.6 million for Q3 2025 at Spero Therapeutics, down from $2.5 million in the prior quarter.
- Across five years, Receivables - Other topped out at $8.5 million in Q1 2021 and bottomed at $668000.0 in Q1 2025.
- Average Receivables - Other over 5 years is $2.6 million, with a median of $2.1 million recorded in 2023.
- The sharpest move saw Receivables - Other skyrocketed 227.02% in 2023, then crashed 86.69% in 2025.
- Year by year, Receivables - Other stood at $2.6 million in 2021, then tumbled by 58.95% to $1.1 million in 2022, then surged by 42.53% to $1.5 million in 2023, then soared by 99.68% to $3.1 million in 2024, then crashed by 48.43% to $1.6 million in 2025.
- Business Quant data shows Receivables - Other for SPRO at $1.6 million in Q3 2025, $2.5 million in Q2 2025, and $668000.0 in Q1 2025.